argenx SE (EBR:ARGX)

Market Cap	47.19B
Revenue (ttm)	3.14B
Net Income (ttm)	1.31B
Shares Out	61.20M
EPS (ttm)	19.83
PE Ratio	38.87
Forward PE	36.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,338
Average Volume	78,051
Open	791.40
Previous Close	792.20
Day's Range	765.60 - 791.40
52-Week Range	456.60 - 810.00
Beta	-0.11
RSI	51.93
Earnings Date	Feb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,599
• Stock Exchange: Euronext Brussels
• Ticker Symbol: ARGX

Financial Performance

Financial numbers in USD